# A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

> **NCT07736950** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Australasian Leukaemia and Lymphoma Group** · enrollment: 140 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Surovatamig
- **RADIATION:** Involved Site Radiotherapy (ISRT)
- **RADIATION:** Involved-Site Radiotherapy (ISRT) + Rituximab

## Key facts

- **NCT ID:** NCT07736950
- **Lead sponsor:** Australasian Leukaemia and Lymphoma Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-12
- **Primary completion:** 2035-01-13
- **Final completion:** 2035-01-13
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736950, "A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*